Lawmakers seek the removal of Glavin

Share this article:
FDA associate commissioner for regulatory affairs Margaret O'K. Glavin should be removed from her post for sending a "retaliatory" all-hands memo to the agency's field employees shortly after congressional testimony by several dissident field managers gave the agency low grades for its food inspection performance, House Energy and Commerce leaders said in a letter to FDA commissioner Andrew von Eschenbach.

“(G)iven Ms. Glavin's blatant conduct, she should be removed from her position directing FDA field staff and replaced by someone who truly believes in reforming the way the FDA does business,” Oversight and Investigations Subcommittee chairman Bart Stupak (D-MI) was quoted in a news release as saying.

“At the same time, the commissioner needs to publicly repudiate and condemn her statements as contrary to the law and his policies at the FDA,” he continued.

Glavin's conduct could be a federal law violation, said full committee chairman John Dingell (D-MI). He added that her memo contradicted  previous testimony by von Eschenbach about not tolerating intimidation or retaliation of any kind.

Dingell is sponsoring a bill to prevent the FDA from proceeding with a plan by Glavin to close seven of the agency's 13 field laboratories and consolidate district offices, and to require any future closings to first gain congressional approval.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...